Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Habenbacher, M; Moser, U; Abaira, A; Kiss, P; Holzmeister, C; Pock, J; Walla, K; Lang, A; Andrianakis, A.
Clinical effectiveness of dupilumab in CRSwNP: unaffected by baseline nasal polyp size in real-world settings.
Eur Arch Otorhinolaryngol. 2025;
Doi: 10.1007/s00405-025-09275-2
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Andrianakis Alexandros
- Habenbacher Michael
- Co-authors Med Uni Graz
- Holzmeister Clemens
- Kiss Peter
- Lang Angelika
- Moser Ulrich Christian
- Pock Jakob
- Walla Katharina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: This study aimed to investigate the impact of baseline nasal polyp score (NPS) on the effectiveness of dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: In this retrospective observational study, 80 CRSwNP patients treated with dupilumab 300 mg biweekly at a tertiary referral center were stratified according to the baseline NPS into two groups: low-NPS (< 5) and high-NPS (≥ 5). Treatment outcomes were evaluated at the 6-month follow-up visit and compared. RESULTS: Both groups showed significant clinical improvements. The NPS decreased significantly in both low- and high-NPS groups, from a mean score of 3.2 to 0.8 and from 6.1 to 1.4, respectively (p < 0.001 for both). SNOT-22 scores improved significantly in both groups (p < 0.001 for both), though the reduction was greater in the high-NPS group (35.5 vs. 23.9, p = 0.018). There were no significant differences between low- and high NPS groups in proportions of NPS reduction of ≥ 1 (89% vs. 95%, p = 0.396) and clinically significant SNOT-22 improvement (= reduction > 12 or follow-up SNOT < 40; 80% vs. 86%, p = 0.544). CONCLUSIONS: Our results suggests that dupilumab is effective in CRSwNP treatment, regardless of baseline nasal polyp size. Both small and large polyp groups showed significant improvements in NPS and patient-reported outcome measures. Future, prospective studies are warranted to validate these findings.
- Find related publications in this database (Keywords)
- Chronic rhinosinusitis
- CRSwNP
- Biological treatment
- Monoclonal antibody